Innovation Pharmaceuticals Inc (IPIX)

[MinnieM]

Brilacidin items of importance that are basic to know for those without medical training.

Brilacidin has passed safety benchmarks in multiple clinical trials and, is currently being tested as a covid therapeutic in two US RBL’s.

Brilacidin for ABSSSI is ph3 ready. Ph2 was dosed via IV in hundreds of patients.

Brilacidin for OM is ph3 ready. Ph2 was dosed via swish and spit.

Brilacidin for UP ph 2 POC trial was dosed with water enema. Results good enough that Alfasigma licensed Brilacidin for UP dosing with foam, enema, or gel.

Brilacidin for UC ph 1 was dosed with Oralogic tablet.

*****

http://www.ipharminc.com/press-release/2020/5/26/innovation-pharmaceuticals-receives-data-from-public-health-research-institute-showing-brilacidin-inhibits-sars-cov-2-covid-19-in-a-human-cell-line

· Brilacidin showed a dose-dependent inhibitory response in a human kidney cell line expressing hACE2
· Data supports Brilacidin’s potential to prevent SARS-CoV-2 binding to the hACE2 receptor, the method by which the novel coronavirus gains entry in human cells

*****

https://www.globenewswire.com/news-release/2020/06/11/2046799/0/en/Innovation-Pharmaceuticals-Collaborating-with-Regional-Biocontainment-Lab-on-Grant-Application-to-Research-Brilacidin-as-a-Pan-Coronavirus-Therapeutic.html

a clinical stage biopharmaceutical company, announces today the Company and researchers at a U.S. Regional Biocontainment Laboratory (RBL) are collaborating on a federal grant application to be submitted this week.

This is likely to have been submitted on Friday the 12th and, that is the date I’ll be using for my purposes.

The proposed research aims to evaluate Brilacidin as a potential pan-coronavirus therapeutic, for treating SARS-CoV-2, SARS-CoV-1 and MERS-CoV, including extending the current in vitro testing of Brilacidin to in vivo testing.

With grant approval they will likely move into in vivo testing asap. This means animals or clinical trials. Given the global concern, this is when I expect human trials to start using IV dosing.

The question remains as to whether or not this grant is approved. This will be helped by the fact testing is being conducted by US RBL's and not internal company testing.

Again, due to global concern and the fact that Brilacidin has been safely administered to hundreds of humans in clinical trials, I’m expecting it to be approved. I also expect expedited approval due the global concern.

Probability is finally on our side as shareholders due to the seriousness and intensity of the global concern surrounding covid. And, I don’t believe Leo would make false covid claims with the SEC watching this arena closely.

SEC Charges Companies and CEO for Misleading COVID-19 Claims
https://www.sec.gov/news/press-release/2020-111

We are actively monitoring the markets to detect potential fraudsters who seek to use the COVID-19 crisis as a basis for investment scams,” said Stephanie Avakian, Co-Director of the SEC’s Division of Enforcement.

Good luck to all…